1. Home
  2. ZYME vs ALEX Comparison

ZYME vs ALEX Comparison

Compare ZYME & ALEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYME
  • ALEX
  • Stock Information
  • Founded
  • ZYME 2003
  • ALEX 1870
  • Country
  • ZYME United States
  • ALEX United States
  • Employees
  • ZYME N/A
  • ALEX N/A
  • Industry
  • ZYME Biotechnology: Pharmaceutical Preparations
  • ALEX Real Estate Investment Trusts
  • Sector
  • ZYME Health Care
  • ALEX Real Estate
  • Exchange
  • ZYME Nasdaq
  • ALEX Nasdaq
  • Market Cap
  • ZYME 1.2B
  • ALEX 1.2B
  • IPO Year
  • ZYME 2017
  • ALEX N/A
  • Fundamental
  • Price
  • ZYME $16.46
  • ALEX $15.46
  • Analyst Decision
  • ZYME Strong Buy
  • ALEX Buy
  • Analyst Count
  • ZYME 7
  • ALEX 2
  • Target Price
  • ZYME $22.00
  • ALEX $24.00
  • AVG Volume (30 Days)
  • ZYME 889.7K
  • ALEX 415.8K
  • Earning Date
  • ZYME 11-06-2025
  • ALEX 10-30-2025
  • Dividend Yield
  • ZYME N/A
  • ALEX 5.80%
  • EPS Growth
  • ZYME N/A
  • ALEX 65.09
  • EPS
  • ZYME N/A
  • ALEX 1.01
  • Revenue
  • ZYME $134,481,000.00
  • ALEX $226,062,000.00
  • Revenue This Year
  • ZYME $99.52
  • ALEX N/A
  • Revenue Next Year
  • ZYME N/A
  • ALEX $2.00
  • P/E Ratio
  • ZYME N/A
  • ALEX $15.39
  • Revenue Growth
  • ZYME 116.21
  • ALEX N/A
  • 52 Week Low
  • ZYME $9.03
  • ALEX $15.43
  • 52 Week High
  • ZYME $19.98
  • ALEX $19.97
  • Technical
  • Relative Strength Index (RSI)
  • ZYME 36.30
  • ALEX 26.04
  • Support Level
  • ZYME $17.27
  • ALEX $15.52
  • Resistance Level
  • ZYME $19.98
  • ALEX $15.85
  • Average True Range (ATR)
  • ZYME 0.76
  • ALEX 0.29
  • MACD
  • ZYME -0.27
  • ALEX -0.07
  • Stochastic Oscillator
  • ZYME 11.48
  • ALEX 3.29

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About ALEX Alexander & Baldwin Inc. REIT Holding Company

Alexander & Baldwin Inc is a Hawaii commercial real estate company. The group owns, operates, and manages million square feet of retail, industrial, and office space in Hawaii. It is a real estate investment trust (REIT) and the owner of grocery and drug-anchored retail centers in the state. It functions through two segments namely Commercial Real Estate and Land Operations. The Commercial Real Estate segment owns and manages retail, industrial spaces, and also urban ground leases in Hawaii, thereby accounting for a majority of the company's revenue. The Land Operations segment actively manages the company's land and real estate-related assets and makes optimum utilization of these assets. Geographically, the activities are carried out across the United States.

Share on Social Networks: